- Details
- Description
Packaging Size:
56c/bottle
Strength:
150mg
Composition:
Alectinib
Treatment:
Anaplastic lymphoma kinase (ALK)-positive metastasis non-small cell lung cancer (NSCLC)
Form:
Capsule
Brand:
Alynni
Quantity Unit:
150mg*56C/Bottle
Manufacturer:
Tongmeng (Lao) Pharmaceutical & Food Co., Ltd.（TLPH）
Alectinib is a type of cancer growth blocker called a tyrosine kinase inhibitor. It works by blocking certain chemical messengers that tell cells to grow. This stops or slows down the cancer.
Approval in Japan
Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma .
Non-small Cell Lung Cancer
Indicated for anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test 600 mg PO BID until disease progression or unacceptable toxicity See AdministrationDosage Modifications
Dose reduction schedule
- Starting dose: 600 mg PO BID
- First dose reduction: 450 mg PO BID
- Second dose reduction: 300 mg PO BID
- Discontinue if patients are unable to tolerate 300 mg PO BID
